Sean Nolan is Chief Executive Officer and Director of Taysha Gene Therapies, Inc. (TSHA). The company reported total compensation of $4,099,065 for fiscal year 2025.
| Salary | $645,840 |
|---|---|
| Bonus | $0 |
| Stock awards | $1,651,125 |
| Option awards | $1,258,425 |
| Non-equity incentive plan | $542,506 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $1,169 |
| Total | $4,099,065 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Taysha Gene Therapies, Inc. filed April 22, 2026, accession 0001193125-26-168525.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | Chief Executive Officer and Director | $645,840 | $0 | $1,651,125 | $1,258,425 | $542,506 | $0 | $1,169 | $4,099,065 |
| FY2024 | Chief Executive Officer and Director | $621,000 | $0 | $2,025,816 | $1,670,410 | $409,860 | $0 | $774 | $4,727,861 |
Totals as disclosed in each year's own compensation disclosure for Taysha Gene Therapies, Inc..
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Sean Nolan this page | Chief Executive Officer and Director | $4,099,065 |
| Kamran Alam | Chief Financial Officer | $2,146,964 |
| Sukumar Nagendran | President and Head of Research and Development and Director | $2,092,890 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Taysha Gene Therapies, Inc. compensation brief.
Sean Nolan's compensation sits inside Taysha Gene Therapies, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.